Licarin A CAS NO.23518-30-1

Meso-dihydroguaiaretic acid and licarin A of Machilus thunbergii protect against glutamate-induced toxicity in primary cultures of a rat cortical cells.[Pubmed: 16151440]

Br J Pharmacol. 2005 Nov;146(5):752-9.

We previously reported that four lignans isolated from the bark of Machilus thunbergii Sieb. et Zucc. (Lauraceae) protected primary cultures of rat cortical neurons from neurotoxicity induced by glutamate.
METHODS AND RESULTS:
2 Among the lignans, meso-dihydroguaiarectic acid (MDGA) and Licarin A significantly attenuated glutamate-induced neurotoxicity when added prior to or right after the excitotoxic glutamate challenge. 3 The neuroprotective activities of two lignans appeared to be more effective in protecting neurons against neurotoxicity induced by NMDA than that induced by kainic acid. 4 MDGA and Licarin A diminished the calcium influx that routinely accompanies with the glutamate-induced neurotoxicity, and inhibited the subsequent overproduction of cellular nitric oxide and peroxide to the level of control cells. They also preserved cellular activities of antioxidative enzymes such as superoxide dismutase, glutathione peroxidase and glutathione reductase reduced in the glutamate-injured neuronal cells.
CONCLUSIONS:
5 Thus, our results suggest that MDGA and Licarin A significantly protect primary cultured neuronal cells against glutamate-induced oxidative stress, via antioxidative activities.

Neolignan Licarin A presents effect against Leishmania (Leishmania) major associated with immunomodulation in vitro.[Pubmed: 23891943]

Exp Parasitol. 2013 Oct;135(2):307-13.

Leishmaniasis' treatment is based mostly on pentavalent antimonials or amphotericin B long-term administration, expensive drugs associated with severe side effects. Considering these aforementioned, the search for alternative effective and safe leishmaniasis treatments is a necessity.
METHODS AND RESULTS:
This work evaluated a neolignan, Licarin A anti-leishmanial activity chemically synthesized by our study group. It was observed that Licarin A effectively inhibited Leishmania (Leishmania) major promastigotes (IC?? of 9.59 ± 0.94 μg/mL) growth, by inducing in these parasites genomic DNA fragmentation in a typical death pattern by apoptosis. Additionally, the neolignan proved to be even more active against intracellular amastigotes of the parasite (EC?? of 4.71 ± 0.29 μg/mL), and significantly more effective than meglumine antimoniate (EC?? of 216.2 ± 76.7 μg/mL) used as reference drug. The antiamastigote activity is associated with an immunomodulatory activity, since treatment with Licarin A of the infected macrophages induced a decrease in the interleukin (IL)-6 and IL-10 production.
CONCLUSIONS:
This study demonstrates for the first time the antileishmanial activity of Licarin A and suggests that the compound may be a promising in the development of a new leishmanicidal agent.

Schistosomicidal and trypanocidal structure-activity relationships for (±)-licarin A and its (-)- and (+)-enantiomers.[Pubmed: 21570099]

Phytochemistry. 2011 Aug;72(11-12):1424-30.

(±)-Licarin A (1) was obtained by oxidative coupling, and its enantiomers, (-)-Licarin A (2) and (+)-Licarin A (3), were resolved by chiral HPLC.
METHODS AND RESULTS:
Schistosomicidal and trypanocidal activities of these compounds were evaluated in vitro against Schistosoma mansoni adult worms and trypomastigote forms of Trypanosoma cruzi. The racemic mixture (1) displayed significant schistosomicidal activity with an LC?? value of 53.57 μM and moderate trypanocidal activity with an IC?? value of 127.17 μM. On the other hand, the (-)-enantiomer (2), displaying a LC?? value of 91.71 μM, was more active against S. mansoni than the (+)-enantiomer (3), which did not show activity. For the trypanocidal assay, enantiomer 2 showed more significant activity (IC?? of 23.46 μM) than enantiomer 3, which showed an IC?? value of 87.73 μM.
CONCLUSIONS:
Therefore, these results suggest that (±)-Licarin A (1) and (-)-Licarin A (2) are promising compounds that could be used for the development of schistosomicidal and trypanocidal agents.

Antitubercular activity and the subacute toxicity of (-)-Licarin A in BALB/c mice: a neolignan isolated from Aristolochia taliscana.[Pubmed: 23291382]

Arch Med Res. 2013 Feb;44(2):99-104.

(-)-Licarin A (LA) was isolated from diverse plants such as Aristolochia taliscana and possesses antimycobacterial, antiinflammatory, trypanocidal, and neuroprotective activities. The aim of the study was to determine the antitubercular and subacute toxicity of (-)-Licarin A isolated from A. taliscana in BALB/c mice.
METHODS AND RESULTS:
The antitubercular activity of (-)-Licarin A was tested in a TB murine model inducing disease with M. tuberculosis H37Rv or MDR. Mice were treated with (-)-Licarin A (5 mg/kg) for 30 and 60 days; post/treatment, lung bacilli loads and pneumonia percentage were determined. The subacute toxicity of (-)-Licarin A (21 days) was evaluated in healthy mice. After treatment, biochemical and hematological parameters were determined and main organs were analyzed histologically. In animals infected with drug-sensitive or MDR strains, (-)-Licarin A produced a significant decrease of pulmonary bacillary burdens at day 30 of treatment, and a significant pneumonia reduction at days 30 and 60 of treatment. Regarding subacute toxicity, (-)-Licarin A administration during 21 days showed no abnormalities in main-organ macro- and microarchitecture.
CONCLUSIONS:
(-)-Licarin A reduces pneumonia of mice infected with both mycobacterium strains. Also, subacute toxicity of (-)-Licarin A exhibits no major signs of damage. Biochemical and hematological parameters and histological analyses indicate that (-)-Licarin A caused no significant changes at the doses assayed.